Aquinox Pharmaceuticals Announces Year End 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
Aquinox Pharmaceutical (AQXP) PT Lifted to $17 at Canaccord Genuity
March 17, 2015 8:46 AM EDTCanaccord Genuity analyst Corey Davis reiterated a Buy rating and lifted his price target on Aquinox Pharmaceutical (NASDAQ: AQXP) to $17.00 (from $12.00) following Q4 results.
Davis commented, "Auinox reported Q4 tonight, and for 2014 logged an adjusted net loss of $22.0M versus our projected $21.4M. While numbers matter little for a R&D-driven story, the... More
